Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
Portfolio Pulse from Nina Zdinjak
Mydecine Innovations Group, a biotech company focused on psychedelic-based drugs, has begun trading on the UK's AQSE Growth Market under the ticker MYIG. The company is at a pivotal phase in its development and is working on its 2nd generation molecules, with human clinical studies expected to commence in 2024. Mydecine shares closed 28.19% higher at 0.12 cents per share.
October 12, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mydecine Innovations Group's shares closed 28.19% higher after the company began trading on the UK's AQSE Growth Market.
The company's listing on the AQSE Growth Market has increased its exposure to UK and European investors, which likely contributed to the rise in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100